Pulmatrix Inc.
Organization details
- Legal name
- Pulmatrix Inc.
- Former names
- Ruthigen, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Framingham
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- PULM
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001574235
- EIN
- 46-1821392
Board of directors
-
Anand Varadan · DirectorSince 2023
-
Christopher Cabell · DirectorSince 2023
-
Michael J. Higgins · DirectorSince 2023
-
Richard P. Batycky · DirectorSince 2023
-
Teofilo David Raad · Director · Chief Executive OfficerSince 2023
-
Todd Bazemore · DirectorSince 2023
Chief executives
Director election results
Annual meeting of October 26, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
87.9%
-
89.9%
Board connections
2 of this board's directors also sit on 4 other boards. 4 are in the same sector.
-
CAMP4 Therapeutics Corporation Same sectorvia Michael J. Higgins
-
KALA BIO Inc. Same sectorvia Todd Bazemore
-
Korsana Biosciences Inc. Same sectorvia Michael J. Higgins
-
Voyager Therapeutics Inc. Same sectorvia Michael J. Higgins
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Pulmatrix Inc.
Who is the CEO of Pulmatrix Inc.?
Teofilo David Raad is Pulmatrix Inc.'s Chief Executive Officer.
How many directors are on Pulmatrix Inc.'s board?
Pulmatrix Inc.'s board has 6 directors: Anand Varadan, Christopher Cabell, Michael J. Higgins, Richard P. Batycky, Teofilo David Raad and Todd Bazemore.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="pulmatrix-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.